|Day Low/High||26.63 / 27.11|
|52 Wk Low/High||10.94 / 27.79|
You should be thinking positively these days if your stock has had a run or even if it hasn't as a preponderance of good things is liable to happen.
Entwistle & Cappucci LLP ("Entwistle & Cappucci") today announced that it has filed a securities class action lawsuit on behalf of persons or entities that purchased call options and/or sold put options on Valeant Pharmaceuticals International, Inc.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending market topics from the floor of the New York Stock Exchange.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer thinks Barclay's $29 price target on Valeant Pharmaceuticals is "very right."
LAVAL, Quebec, June 1, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMGN, CIG.C, COTV, CTRE, GMS, HPT, IAG, NFEC, QGEN, SCVL, THR, TPHS, USFD, UVV Downgrades: BKE, IGT, TSLX, VRX Initiations: MGEN Read on to get TheStreet Quant Ratings' detailed report:
Jim Cramer weighs in on Royal Caribbean, Allergan, Tyson Foods, Carrizo Oil & Gas, Valeant Pharmaceuticals, Okta, CRISPR Therapeutics and more.
Jim Cramer says the hope that the trade dispute with China can be worked out was the fuel for this rally.
All three major averages closed Thursday's session in positive territory.
Valeant Pharmaceuticals is changing its name to Bausch Health and the stock is a buy, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.
Jim Cramer says the reason this market is so hard to deal with is that it doesn't know how to calculate an event -- even when everyone saw it coming.
Stocks finished mixed on Tuesday after President Trump announced that the U.S. would withdraw from the Iran nuclear deal.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending stocks from the floor of the New York Stock Exchange.
Valeant will become Bausch Health Cos. this summer. Here's what that could mean for the company as it continues to recover from controversy.
Jim Cramer takes a look at CVS Health, Prestige Brands, LendingTree, Valeant Pharmaceuticals, Nektar Therapeutics, Kirkland Lake and more.
Jim Cramer says Warren Buffett is the greatest investor, and his optimism has suffused trading and has been justified.
Wall Street is 'drunk on bitcoin nonsense,' Left says. He tells TheStreet why his Citron Research is taking an unpopular stance on Square.
Masco's 4% drop Thursday is the latest proof that big call buying doesn't mean insiders know something you don't.
Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.
Jim Cramer focuses on American Airlines, Salesforce.com, Realty Income, Proctor & Gamble, United Bankshares, iRobot, Dominion Energy.
Good earnings reports, cooling oil, and tech leadership all contributed to Thursday's gains, says Jim Cramer. Along with no explosive presidential tweets.
Tesla's Model Y could begin production in November 2019, but don't get your hopes up.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
The embattled activist is reportedly experiencing significant redemptions as investors seek to flee his fund. A campaign at the payroll processor in 2018 is a real possibility as Ackman has $500 million committed to a co-investment targeting the company
Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.